Capricor Therapeutics
CAPR
30 hedge funds and large institutions have $20.5M invested in Capricor Therapeutics in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 4 closing their positions.
299% more capital invested
Capital invested by funds: $5.14M → $20.5M (+$15.4M)
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
20% more funds holding
Funds holding: 25 → 30 (+5)
11.9% more ownership
Funds ownership: 7.33% → 19.23% (+12%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
36% less call options, than puts
Call options by funds: $1.04M | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$11.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.49M |
| 3 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$1.56M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$285K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$373K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$230K |
| 3 |
Millennium Management
New York
|
-$155K |
| 4 |
Morgan Stanley
New York
|
-$145K |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $2K | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
28
Fidelity Investments
Boston,
Massachusetts
| $1K | +$1.3K | +225 | New |
|
|
BBHC
29
Brown Brothers Harriman & Co
New York
| $24 | +$29.4K | +5,112 | New |
|
|
30
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| – | -$54K | -15,750 | Closed |
|
|
OQS
31
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$52K | -15,188 | Closed |
|
32
Charles Schwab
San Francisco,
California
| – | -$50K | -14,545 | Closed |
|
33
Citigroup
New York
| – | -$3K | -900 | Closed |
|
34
Barclays
London,
United Kingdom
| – | +$564 | +98 | New |
|
CAPR Hedge Fund Activity: Q1 2021 in Review
30 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2021, worth a combined $20.5M — up 299% from $5.14M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CAPR positions and 4 closed out — a net gain of 5 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Oracle Investment Management, opening a new position worth an estimated $11.5M. The largest seller was GSA Capital Partners, cutting an estimated $373K.
- 30 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2021, up from 25 in Q4 2020.
- Funds reported $20.5M of Capricor Therapeutics stock for Q1 2021, up 299% quarter-over-quarter.
- 9 funds opened new Capricor Therapeutics positions in Q1 2021 and 4 closed out, a net change of +5 holders.
- The largest Capricor Therapeutics buyer in Q1 2021 was Oracle Investment Management, an estimated $11.5M added.
- The largest Capricor Therapeutics seller in Q1 2021 was GSA Capital Partners, an estimated $373K sold.
Based on aggregated 13F filings for Q1 2021.